Guard Therapeutics (Sweden) Performance
| GUARD Stock | SEK 1.54 0.06 4.05% |
The company retains a Market Volatility (i.e., Beta) of 0.82, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Guard Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Guard Therapeutics is expected to be smaller as well. At this point, Guard Therapeutics has a negative expected return of -1.73%. Please make sure to check out Guard Therapeutics' standard deviation, kurtosis, relative strength index, as well as the relationship between the maximum drawdown and day median price , to decide if Guard Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Guard Therapeutics International has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in February 2026. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Guard |
Guard Therapeutics Relative Risk vs. Return Landscape
If you would invest 2,080 in Guard Therapeutics International on October 11, 2025 and sell it today you would lose (1,926) from holding Guard Therapeutics International or give up 92.6% of portfolio value over 90 days. Guard Therapeutics International is generating negative expected returns and assumes 13.2888% volatility on return distribution over the 90 days horizon. Simply put, majority of traded equity instruments are less risky than Guard on the basis of their historical return distribution, and most equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Guard Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Guard Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Guard Therapeutics International, and traders can use it to determine the average amount a Guard Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1305
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | GUARD |
Estimated Market Risk
| 13.29 actual daily | 96 96% of assets are less volatile |
Expected Return
| -1.73 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.13 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Guard Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Guard Therapeutics by adding Guard Therapeutics to a well-diversified portfolio.
Guard Therapeutics Fundamentals Growth
Guard Stock prices reflect investors' perceptions of the future prospects and financial health of Guard Therapeutics, and Guard Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Guard Stock performance.
| Return On Equity | -1.53 | |||
| Return On Asset | -0.75 | |||
| Current Valuation | 120.17 M | |||
| Shares Outstanding | 503.08 M | |||
| Price To Book | 2.97 X | |||
| EBITDA | (82.03 M) | |||
| Cash And Equivalents | 188.6 M | |||
| Cash Per Share | 0.44 X | |||
| Debt To Equity | 0 % | |||
| Book Value Per Share | 0.30 X | |||
| Cash Flow From Operations | (77.59 M) | |||
| Earnings Per Share | (0.34) X | |||
| Total Asset | 190.44 M | |||
About Guard Therapeutics Performance
Assessing Guard Therapeutics' fundamental ratios provides investors with valuable insights into Guard Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Guard Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Guard Therapeutics International AB , a pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden. Guard Therapeutics International AB was incorporated in 2008 and is based in Stockholm, Sweden. Guard Therapeutics is traded on Stockholm Stock Exchange in Sweden.Things to note about Guard Therapeutics performance evaluation
Checking the ongoing alerts about Guard Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Guard Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Guard Therapeutics generated a negative expected return over the last 90 days | |
| Guard Therapeutics has high historical volatility and very poor performance | |
| Guard Therapeutics may become a speculative penny stock | |
| Guard Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (82.03 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Guard Therapeutics International has accumulated about 188.6 M in cash with (77.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.44. | |
| Roughly 30.0% of the company shares are held by company insiders |
- Analyzing Guard Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Guard Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Guard Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Guard Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Guard Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Guard Therapeutics' stock. These opinions can provide insight into Guard Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Guard Stock Analysis
When running Guard Therapeutics' price analysis, check to measure Guard Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Guard Therapeutics is operating at the current time. Most of Guard Therapeutics' value examination focuses on studying past and present price action to predict the probability of Guard Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Guard Therapeutics' price. Additionally, you may evaluate how the addition of Guard Therapeutics to your portfolios can decrease your overall portfolio volatility.